Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRXGet Rating) in a report issued on Wednesday. The firm set a “sell” rating on the stock.

Shares of NASDAQ MBRX opened at $1.33 on Wednesday. The stock’s fifty day moving average is $1.63 and its 200 day moving average is $1.77. The stock has a market capitalization of $38.01 million, a P/E ratio of -2.11 and a beta of 1.83. Moleculin Biotech has a 52 week low of $1.02 and a 52 week high of $3.99.

Moleculin Biotech (NASDAQ:MBRXGet Rating) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.03). Research analysts anticipate that Moleculin Biotech will post -0.94 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in MBRX. Morgan Stanley acquired a new stake in Moleculin Biotech in the first quarter valued at about $39,000. Renaissance Technologies LLC acquired a new stake in shares of Moleculin Biotech during the fourth quarter valued at about $62,000. Sigma Planning Corp acquired a new stake in shares of Moleculin Biotech during the fourth quarter valued at about $80,000. Virtu Financial LLC acquired a new stake in shares of Moleculin Biotech during the fourth quarter valued at about $87,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Moleculin Biotech during the second quarter valued at about $94,000. 10.57% of the stock is currently owned by institutional investors and hedge funds.

About Moleculin Biotech (Get Rating)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

Read More

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.